|
1
|
Takeda K, Kaisho T and Akira S: Toll-like
receptors. Annu Rev Immunol. 21:335–376. 2003. View Article : Google Scholar
|
|
2
|
Takeda K and Akira S: Toll-like receptors
in innate immunity. Int Immunol. 17:1–14. 2005. View Article : Google Scholar
|
|
3
|
Beutler B, Jiang Z, Georgel P, Crozat K,
Croker B, Rutschmann S, et al: Genetic analysis of host resistance:
Toll-like receptor signaling and immunity at large. Annu Rev
Immunol. 24:353–389. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Akira S, Uematsu S and Takeuchi O:
Pathogen recognition and innate immunity. Cell. 124:783–801. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bauer S, Kirschning CJ, Häcker H, Redecke
V, Hausmann S, Akira S, Wagner H and Lipford GB: Human TLR9 confers
responsiveness to bacterial DNA via species-specific CpG motif
recognition. Proc Natl Acad Sci USA. 98:9237–9242. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Becker MN, Diamond G, Verghese MW and
Randell SH: CD14-dependent lipopolysaccharide-induced
beta-defensin-2 expression in human tracheobronchial epithelium. J
Biol Chem. 275:29731–29736. 2000. View Article : Google Scholar
|
|
7
|
Faure E, Thomas L, Xu H, Medvedev A,
Equils O and Arditi M: Bacterial lipopolysaccharide and IFN-gamma
induce Toll-like receptor 2 and Toll-like receptor 4 expression in
human endothelial cells: role of NF-kappa B activation. J Immunol.
166:2018–2024. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Barton GM, Kagan JC and Medzhitov R:
Intracellular localization of Toll-like receptor 9 prevents
recognition of self-DNA but facilitates access to viral DNA. Nat
Immunol. 7:49–56. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yamamoto M, Sato S, Hemmi H, Hoshino K,
Kaisho T, Sanjo H, Takeuchi O, Sugiyama M, Okabe M, Takeda K and
Akira S: Role of adaptor TRIF in the MyD88-independent toll-like
receptor signaling pathway. Science. 301:640–643. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Alexopoulou L, Holt AC, Medzhitov R and
Flavell RA: Recognition of double-stranded RNA and activation of
NF-kappaB by Toll-like receptor 3. Nature. 413:732–738. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Khvalevsky E, Rivkin L, Rachmilewitz J,
Galun E and Giladi H: TLR3 signaling in a hepatoma cell line is
skewed towards apoptosis. J Cell Biochem. 100:1301–1312. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Huang B, Zhao J, Unkeless JC, Feng ZH and
Xiong H: TLR signaling by tumor and immune cells: a double-edged
sword. Oncogene. 27:218–224. 2008. View Article : Google Scholar
|
|
13
|
Yu L and Chen S: Toll-like receptors
expressed in tumor cells: targets for therapy. Cancer Immunol
Immunother. 57:1271–1278. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sato Y, Goto Y, Narita N and Hoon DS:
Cancer cells expressing Toll-like receptors and the tumor
microenvironment. Cancer Microenviron. 2:205–214. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yoneda K, Sugimoto K, Shiraki K, Tanaka J,
Beppu T, Fuke H, Yamamoto N, Masuya M, Horie R, Uchida K and Takei
Y: Dual topology of functional Toll-like receptor 3 expression in
human hepatocellular carcinoma: Differential signaling mechanisms
of TLR3-induced NF-kappaB activation and apoptosis. Int J Oncol.
33:929–936. 2008.PubMed/NCBI
|
|
16
|
Tanaka J, Sugimoto K, Shiraki K, Tameda M,
Kusagawa S, Nojiri K, Beppu T, Yoneda K, Yamamoto N, Uchida K,
Kojima T and Takei Y: Functional cell surface expression of
toll-like receptor 9 promotes cell proliferation and survival in
human hepatocellular carcinomas. Int J Oncol. 37:805–814.
2010.PubMed/NCBI
|
|
17
|
Sun R, Zhang Y, Lv Q, Liu B, Jin M, Zhang
W, He Q, Deng M, Liu X, Li G, Li Y, Zhou G, Xie P, Xie X, Hu J and
Duan Z: Toll-like receptor 3 (TLR3) induces apoptosis via death
receptors and mitochondria by up-regulating the transactivating p63
isoform alpha (TAP63alpha). J Biol Chem. 286:15918–15928. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Salaun B, Lebecque S, Matikainen S,
Rimoldi D and Romero P: Toll-like receptor 3 expressed by melanoma
cells as a target for therapy? Clin Cancer Res. 13:4565–4574. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Honda K, Yanai H, Mizutani T, Negishi H,
Shimada N, Suzuki N, Ohba Y, Takaoka A, Yeh WC and Taniguchi T:
Role of a transductional-transcriptional processor complex
involving MyD88 and IRF-7 in Toll-like receptor signaling. Proc
Natl Acad Sci USA. 101:15416–15421. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kawai T, Sato S, Ishii KJ, Coban C, Hemmi
H, Yamamoto M, Terai K, Matsuda M, Inoue J, Uematsu S, Takeuchi O
and Akira S: Interferon-alpha induction through Toll-like receptors
involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat
Immunol. 5:1061–1068. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Karin M, Cao Y, Greten FR and Li ZW:
NF-kappaB in cancer: from innocent bystander to major culprit. Nat
Rev Cancer. 2:301–310. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ghosh S and Karin M: Missing pieces in the
NF-κB puzzle. Cell. 109:S81–S96. 2002.
|
